Suppr超能文献

三种治疗药物生物等效性研究的两阶段适应性设计

Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies.

作者信息

Grayling Michael J, Mander Adrian P, Wason James M S

机构信息

Hub for Trials Methodology Research, MRC Biostatistics Unit, Cambridge, UK.

Institute of Health & Society, Newcastle University, Newcastle, UK.

出版信息

Stat Biopharm Res. 2019;11(4):360-374. doi: 10.1080/19466315.2019.1654911. Epub 2019 Sep 6.

Abstract

Bioequivalence (BE) studies are most often conducted as crossover trials, and therefore establishing their required sample size necessitates specification of the within-person variance. Given that this specification is often difficult in practice, there has been great interest in recent years in the use of adaptive designs for BE trials. However, while numerous methods for this have now been presented, their focus has been solely on two-treatment BE studies. In some instances, it will be desired to incorporate more than a single test and reference formulation into a BE trial. It would therefore be useful to establish methodology for the design of adaptive multi-treatment BE trials, to acquire the benefits in the two-treatment setting in this more complex situation. Here, we achieve this for three-treatment studies by extending previously proposed designs for two-treatment trials. First, we discuss the additional design considerations that arise when multiple comparisons are made. Next, an extensive simulation study is employed to compare the performance of the proposed procedures. With this, we demonstrate that two-stage designs with desirable statistical operating characteristics can be readily identified for three-treatment BE trials. Supplementary materials for this article are available online.

摘要

生物等效性(BE)研究大多作为交叉试验进行,因此确定其所需样本量需要明确个体内方差。鉴于在实际操作中往往难以进行这种明确,近年来人们对在BE试验中使用适应性设计产生了浓厚兴趣。然而,尽管现在已经提出了许多用于此目的的方法,但它们仅专注于双处理BE研究。在某些情况下,希望在BE试验中纳入不止一种测试制剂和参比制剂。因此,建立适应性多处理BE试验的设计方法,以便在这种更复杂的情况下获得双处理试验中的益处,将是很有用的。在此,我们通过扩展先前为双处理试验提出的设计,实现了三处理研究的这一目标。首先,我们讨论进行多重比较时出现的额外设计考虑因素。接下来,进行广泛的模拟研究以比较所提出程序的性能。通过这样做,我们证明了对于三处理BE试验,可以很容易地确定具有理想统计操作特性的两阶段设计。本文的补充材料可在线获取。

相似文献

1
Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies.
Stat Biopharm Res. 2019;11(4):360-374. doi: 10.1080/19466315.2019.1654911. Epub 2019 Sep 6.
2
Two-stage designs for cross-over bioequivalence trials.
Stat Med. 2015 Jul 20;34(16):2403-16. doi: 10.1002/sim.6487. Epub 2015 Mar 24.
3
Modifications of sequential designs in bioequivalence trials.
Pharm Stat. 2015 May-Jun;14(3):180-8. doi: 10.1002/pst.1672. Epub 2015 Feb 9.
6
Optimal adaptive sequential designs for crossover bioequivalence studies.
Pharm Stat. 2016 Jan-Feb;15(1):15-27. doi: 10.1002/pst.1721. Epub 2015 Nov 5.
7
Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.
Stat Med. 2018 May 10;37(10):1587-1607. doi: 10.1002/sim.7614. Epub 2018 Feb 20.
8
Performance Evaluation of Interim Analysis in Bioequivalence Studies.
Ther Innov Regul Sci. 2024 Sep;58(5):863-881. doi: 10.1007/s43441-024-00664-z. Epub 2024 May 24.
9
Blinded and unblinded sample size reestimation in crossover trials balanced for period.
Biom J. 2018 Sep;60(5):917-933. doi: 10.1002/bimj.201700092. Epub 2018 Aug 3.

引用本文的文献

本文引用的文献

1
Bayesian Two-Stage Adaptive Design in Bioequivalence.
Int J Biostat. 2019 Jul 16;16(1):ijb-2018-0105. doi: 10.1515/ijb-2018-0105.
2
Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
Pharm Stat. 2019 Jan;18(1):96-105. doi: 10.1002/pst.1911. Epub 2018 Oct 29.
3
Adaptive Seamless Design for Establishing Pharmacokinetic and Efficacy Equivalence in Developing Biosimilars.
Ther Innov Regul Sci. 2017 Nov;51(6):761-769. doi: 10.1177/2168479017706526. Epub 2017 May 15.
4
An update on the clinical evidence that supports biosimilar approvals in Europe.
Br J Clin Pharmacol. 2018 Jul;84(7):1415-1431. doi: 10.1111/bcp.13586. Epub 2018 Apr 27.
5
Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.
Stat Med. 2018 May 10;37(10):1587-1607. doi: 10.1002/sim.7614. Epub 2018 Feb 20.
6
A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs.
Eur J Clin Pharmacol. 2018 May;74(5):549-559. doi: 10.1007/s00228-018-2415-7. Epub 2018 Jan 23.
7
Optimal adaptive sequential designs for crossover bioequivalence studies.
Pharm Stat. 2016 Jan-Feb;15(1):15-27. doi: 10.1002/pst.1721. Epub 2015 Nov 5.
8
Two-stage designs for cross-over bioequivalence trials.
Stat Med. 2015 Jul 20;34(16):2403-16. doi: 10.1002/sim.6487. Epub 2015 Mar 24.
9
Modifications of sequential designs in bioequivalence trials.
Pharm Stat. 2015 May-Jun;14(3):180-8. doi: 10.1002/pst.1672. Epub 2015 Feb 9.
10
Sample size calculations for the development of biosimilar products.
J Biopharm Stat. 2014;24(6):1215-24. doi: 10.1080/10543406.2014.941984.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验